HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Innovates Around Water Challenges With Hair Care In South Africa, Liquid-Free DS3

Executive Summary

P&G’s introduction of Waterless hair care in South Africa, where water is a precious commodity, marks the first new retail hair-care brand for the firm in four years. Meanwhile, liquid-free DS3 shampoo, body wash and other personal-care swatches, available now for pre-order, support P&G’s sustainability goals while representing attractive cost efficiencies.

You may also be interested in...



P&G Gives Europe Solid Bars Of Favorite Shampoos In Recyclable Packaging

The sustainable, practical, functionally equivalent bars are fully available across P&G’s European hair care portfolio, including Pantene, Herbal Essences, Aussie, and Head & Shoulders, the last offering antidandruff benefits. P&G highlighted its sustainability progress in conjunction with the launch on World Oceans Day.

Lush Scientist On Firm’s Evolving (And Expensive) Self-Preserving Platform

The testing process for Lush’s self-preserving products can range between $5k to $10k for each self-preserving product, according to cosmetic scientist Daniel Campbell. While resource-intensive, the approach resonates with natural-oriented, ingredient-conscious consumers, and Lush says it ensures that protective microflora on skin and hair aren’t disrupted by synthetic preservative use.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel